AMD

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

The campaign provides tools to patients, researchers, clinicians, industry, and advocates with tools to tell their stories that advocate for vision research.

From blue light blockers to sleep apnea, Jacqueline Theis, OD, FAAO, FNAP; and Joseph Allen, OD, FAAO, Dipl ABO, outlined how sleep can influence brain and ocular health, and vice versa.

A study reveals a genetic link between instant coffee consumption and increased risk of dry age-related macular degeneration, urging caution for high-risk individuals.

deepeye TPS is designed to close the gap between real-world outcomes and trial data by reducing patient dropout.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, presented available treatment options and what is coming down the pipeline for retinal conditions.

From Stargardt to macular telangiectasia type 2, Kensington Hatcher, OD, FAAO, FORS; and Srinivas Kondapalli, MD, detail other conditions that share similarities to AMD.

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

In light of trial results, the company is preparing for financial outcomes dependent on its Development Funding Agreement, warranting a reexamination of Opthea's future.

The grant will allow the research team to determine the novel mechanisms that convert immature eye lens precursors cells into functional transparent cells.

The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.

The study examined changes in genes and proteins of the retinas of 9 strains of mice.

A total of 150 placements are for aspiring optometrists to shadow SpaMedica’s clinical teams and in-house optometrists as they treat patients.

The goal of the agreement is to advance Eleva’s current programs into mid- and late-stage clinical development.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

Nocturnal hypoxia could be a new additional modifiable risk factor for nAMD.